25 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
materials, including due to the COVID-19 pandemic, which may result in additional costs and delays in production of clinical trial materials, commercial … to health epidemics and other outbreaks, such as the COVID-19 pandemic, which could adversely impact Apexigen’s business including Apexigen’s ongoing
S-4/A
PYXS
Pyxis Oncology Inc
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
issues impacting delivery dates, quality, quantity and pricing of raw materials, including due to the COVID-19 pandemic, which may result in additional … of Apexigen’s business.
Other General Risks
Apexigen faces risks related to health epidemics and other outbreaks, such as the COVID-19 pandemic, which could
S-4
PYXS
Pyxis Oncology Inc
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
and pricing of raw materials, including due to the COVID-19 pandemic, which may result in additional costs and delays in production of clinical trial … faces risks related to health epidemics and other outbreaks, such as the COVID-19 pandemic, which could adversely impact Apexigen’s business including
425
APGN
Apexigen Inc
24 May 23
Business combination disclosure
7:05am
, (ii) effects of natural disasters, pandemic outbreaks, hostility, terrorist activity, cyberattacks or declaration or escalation of war or act of public … ” shall mean SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemic or disease outbreaks.
“COVID-19
425
plo5jt0i
24 May 23
Business combination disclosure
7:03am
8-K
EX-2.1
78zerir1nqpvq5h0iabz
24 May 23
Pyxis Oncology to Acquire Apexigen
6:59am
S-3
tverhaxy
1 Nov 22
Shelf registration
4:51pm
DEF 14A
1gmbzw9oeh5fcb31ivr
28 Apr 22
Definitive proxy
4:33pm
10-K
k856d29fzwd
29 Mar 22
Annual report
7:36am
10-Q
EX-3.2
lhm5f zmrbf4bbfu
15 Nov 21
Quarterly report
7:54am
10-Q
s3v3e
15 Nov 21
Quarterly report
7:54am
424B4
pvtmoq6d5l2dvkh8u2
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1/A
EX-3.2
oanq20c6kbt
30 Sep 21
IPO registration (amended)
9:11pm